Noticias y eventos de Cocrystal Pharma Inc (COCP)

$1.120

-0.039 (-3.45%)Al cierre

Noticias de COCP

5.008-17Newsfilter

Cocrystal Pharma Appoints New Board Member

5.006-03NASDAQ.COM

Cocrystal Pharma Appoints New CEO, Shares Rise

9.505-15seekingalpha

Cocrystal Pharma Q1 Earnings Report Analysis

8.504-02stocktwits

Cocrystal Receives FDA Fast Track Designation for CDI-988

9.004-02Newsfilter

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988

9.503-31seekingalpha

Cocrystal Pharma Reports FY 2025 Earnings Results

9.012-18Globenewswire

Cocrystal Receives IRB Approval to Initiate CDI-988 Clinical Trial, Enrollment Expected Q1 2026

1.012-01Globenewswire

Cocrystal Pharma to Present Clinical Progress at NobleCon 21

1.010-02Newsfilter

Cocrystal Pharma to Showcase at Noble Capital Markets Virtual Equity Conference for Emerging Growth Companies

8.509-12SeekingAlpha

Cocrystal Pharma reveals direct offering of up to $13 million.

Ver más noticias

Eventos de COCP

8/3 07:30

Cocrystal Pharma Secures $5M Investment from OPKO Health

Cocrystal Pharma (COCP) announced a $5M investment from OPKO Health (OPK), a longtime investor in the company. Under the terms of the agreement, Cocrystal sold 5,474,053 shares of its common stock to OPKO at a price per share of $0.9134, the Nasdaq Consolidated Bid Price on the trading day of closing, for proceeds to the company of $5M. No warrants or other derivative securities were included in the transaction.

8/3 07:30

Cocrystal Pharma Secures $5M Investment from Opko Health

Cocrystal Pharma (COCP) announced a $5M investment from Opko Health (OPK) as the company advances its lead norovirus program toward Phase 1b topline data later this year. Under the terms of the agreement, Cocrystal sold 5,474,053 shares of its common stock to Opko at a price per share of $0.9134, the Nasdaq consolidated bid price on the trading day of closing, for proceeds to the company of $5M. No warrants or other derivative securities were included in the transaction.

6/3 07:20

Cocrystal Pharma Appoints James Sapirstein as CEO

Cocrystal Pharma has appointed James Sapirstein CEO, effective immediately. The company also plans to appoint Sapirstein as a member of the board of directors. Sapirstein replaces Sam Lee and Jim Martin, who served as co-CEOs. Sam Lee will continue as president and transition to chief scientific officer, and Jim Martin will continue as CFO. Sapirstein was CEO of Contravir Pharmaceuticals.

4/23 19:30

Cocrystal Pharma Files $150M Mixed Securities Shelf

Cocrystal Pharma files $150M mixed securities shelf

4/2 08:20

Cocrystal Pharma Receives FDA Fast Track Designation

Cocrystal Pharma announced that the FDA has granted Fast Track designation to its oral, direct-acting protease inhibitor, CDI-988, the first oral antiviral candidate being developed for treatment and prophylaxis of norovirus infection.

Ver más eventos

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.